AAAAI 2022
Effect of Tezepelumab on Severe Asthma Symptoms in Adults and Adolescents
An analysis of phase 3 NAVIGATOR trial data assessed the effect of tezepelumab on the percentage of asthma symptomatic days in adults and adolescents.
Your search for tezepelumab returned 16 results
News
NAVIGATOR Trial Outcomes for Tezepelumab Use in Severe, Uncontrolled Asthma
An analysis of NAVIGATOR trial data on tezepelumab use assessed patient-reported outcomes related to asthma control, symptoms, and HRQoL.
CHEST 2021, News
Tezepelumab Improves Lung Function in Severe, Uncontrolled Asthma
NAVIGATOR trial results presented at CHEST 2021 show the effect of tezepelumab on peak expiratory flow rates in severe asthma.
Drugs in the Pipeline
Tezepelumab Granted Orphan Drug Status for Eosinophilic Esophagitis
Tezepelumab is a first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin.
News
Tezepelumab Gets Priority Review for Severe Asthma
The BLA submission included data from the pivotal phase 3 NAVIGATOR trial that assessed tezepelumab in 1061 patients with severe, uncontrolled asthma.
Drugs in the Pipeline
Tezepelumab BLA Submitted for Severe Asthma
The BLA submission is supported by data from the PATHFINDER clinical program.
Drugs in the Pipeline
Tezepelumab Cuts Exacerbations in Severe Asthma Trial
Tezepelumab is an investigational first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin.
Drugs in the Pipeline
Tezepelumab Gets Breakthrough Therapy Designation for Severe Asthma
The designation was based on data from the Phase 2b PATHWAY trial that evaluated 3 doses of tezepelumab as add-on therapy in patients with a history of asthma exacerbations and uncontrolled asthma receiving inhaled corticosteroids/long-acting β-agonist with or without oral corticosteroids and additional asthma controllers vs placebo.
ATS 2022
Which Biologics Reduce Allergic Response, Airway Hyperresponsiveness in Asthma?
What biologic therapies effectively treat airway hyperresponsiveness in asthma, and what do these therapies show about the underlying biology of asthma?
